Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors (Review)
- Authors:
- Yoshikuni Inokawa
- Kenichi Inaoka
- Fuminori Sonohara
- Masamichi Hayashi
- Mitsuro Kanda
- Shuji Nomoto
-
Affiliations: Department of Surgery, Aichi Gakuin University School of Dentistry, Nagoya 464‑8651, Japan, Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya 466‑8550, Japan - Published online on: September 15, 2016 https://doi.org/10.3892/ol.2016.5141
- Pages: 3662-3668
This article is mentioned in:
Abstract
Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI | |
Forner A, Vilana R, Ayuso C, Bianchi L, Solé M, Ayuso JR, Boix L, Sala M, Varela M, Llovet JM, et al: Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 47:97–104. 2008. View Article : Google Scholar : PubMed/NCBI | |
Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, Gramantieri L, Zanetti M and Sherman M: Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: A cost effectiveness analysis. Gut. 48:251–259. 2001. View Article : Google Scholar : PubMed/NCBI | |
van Meer S, de Man RA, Siersema PD and van Erpecum KJ: Surveillance for hepatocellular carcinoma in chronic liver disease: Evidence and controversies. World J Gastroenterol. 19:6744–6756. 2013. View Article : Google Scholar : PubMed/NCBI | |
Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI | |
Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, Yoshida H, Kawabe T and Omata M: Percutaneous radiofrequency ablation for hepatocellular carcinoma-An analysis of 1000 cases. Cancer. 103:1201–1209. 2005. View Article : Google Scholar : PubMed/NCBI | |
Llovet JM and Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 37:429–442. 2003. View Article : Google Scholar : PubMed/NCBI | |
Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, et al: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 24:4293–4300. 2006. View Article : Google Scholar : PubMed/NCBI | |
Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, et al: Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 131:461–469. 2006. View Article : Google Scholar : PubMed/NCBI | |
Llovet JM and Bruix J: Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 48(Suppl 1): S20–S37. 2008. View Article : Google Scholar : PubMed/NCBI | |
Morise Z, Kawabe N, Tomishige H, Nagata H, Kawase J, Arakawa S, Yoshida R and Isetani M: Recent advances in the surgical treatment of hepatocellular carcinoma. World J Gastroenterol. 20:14381–14392. 2014. View Article : Google Scholar : PubMed/NCBI | |
Chen X, Liu HP, Li M and Qiao L: Advances in non-surgical management of primary liver cancer. World J Gastroenterol. 20:16630–16638. 2014. View Article : Google Scholar : PubMed/NCBI | |
Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI | |
El-Serag HB and Rudolph L: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI | |
Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW, Lam CT, Poon RT and Fan ST: Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 13:153–166. 2008. View Article : Google Scholar : PubMed/NCBI | |
Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S and Zucman-Rossi J: MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology. 47:1955–1963. 2008. View Article : Google Scholar : PubMed/NCBI | |
Eguchi S, Takatsuki M, Hidaka M, Soyama A, Tomonaga T, Muraoka I and Kanematsu T: Predictor for histological microvascular invasion of hepatocellular carcinoma: A lesson from 229 consecutive cases of curative liver resection. World J Surg. 34:1034–1038. 2010. View Article : Google Scholar : PubMed/NCBI | |
Roayaie S, Jibara G, Taouli B and Schwartz M: Resection of hepatocellular carcinoma with macroscopic vascular invasion. Ann Surg Oncol. 20:3754–3760. 2013. View Article : Google Scholar : PubMed/NCBI | |
Faber W, Stockmann M, Kruschke JE, Denecke T, Bahra M and Seehofer D: Implication of microscopic and macroscopic vascular invasion for liver resection in patients with hepatocellular carcinoma. Dig Surg. 31:204–209. 2014. View Article : Google Scholar : PubMed/NCBI | |
Sumie S, Nakashima O, Okuda K, Kuromatsu R, Kawaguchi A, Nakano M, Satani M, Yamada S, Okamura S, Hori M, et al: The significance of classifying microvascular invasion in patients with hepatocellular carcinoma. Ann Surg Oncol. 21:1002–1009. 2014. View Article : Google Scholar : PubMed/NCBI | |
Tandon P and Garcia-Tsao G: Prognostic indicators in hepatocellular carcinoma: A systematic review of 72 studies. Liver Int. 29:502–510. 2009. View Article : Google Scholar : PubMed/NCBI | |
Poon RT and Fan ST: Hepatectomy for hepatocellular carcinoma: Patient selection and postoperative outcome. Liver Transpl. 10(2): Suppl 1. S39–S45. 2004. View Article : Google Scholar : PubMed/NCBI | |
Pandey D, Lee KH, Wai CT, Wagholikar G and Tan KC: Long term outcome and prognostic factors for large hepatocellular carcinoma (10 cm or more) after surgical resection. Ann Surg Oncol. 14:2817–2823. 2007. View Article : Google Scholar : PubMed/NCBI | |
Ishii T, Hatano E, Yasuchika K, Taura K, Seo S and Uemoto S: High risk of lung metastasis after resection of hepatocellular carcinoma more than 7 cm in diameter. Surg Today. 44:1900–1905. 2014. View Article : Google Scholar : PubMed/NCBI | |
Han JH, Kim DG, Na GH, Kim EY, Lee SH, Hong TH and You YK: Evaluation of prognostic factors on recurrence after curative resections for hepatocellular carcinoma. World J Gastroenterol. 20:17132–17140. 2014. View Article : Google Scholar : PubMed/NCBI | |
Jonas S, Bechstein WO, Steinmüller T, Herrmann M, Radke C, Berg T, Settmacher U and Neuhaus P: Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 33:1080–1086. 2001. View Article : Google Scholar : PubMed/NCBI | |
Han DH, Choi GH, Kim KS, Choi JS, Park YN, Kim SU, Park JY, Ahn SH and Han KH: Prognostic significance of the worst grade in hepatocellular carcinoma with heterogeneous histologic grades of differentiation. J Gastroenterol Hepatol. 28:1384–1390. 2013. View Article : Google Scholar : PubMed/NCBI | |
Scaggiante B, Kazemi M, Pozzato G, Dapas B, Farra R, Grassi M, Zanconati F and Grassi G: Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials. World J Gastroenterol. 20:1268–1288. 2014. View Article : Google Scholar : PubMed/NCBI | |
Giles RH, van Es JH and Clevers H: Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta. 1653:1–24. 2003.PubMed/NCBI | |
Tsao CM, Yan MD, Shih YL, Yu PN, Kuo CC, Lin WC, Li HJ and Lin YW: SOX1 functions as a tumor suppressor by antagonizing the WNT/β-catenin signaling pathway in hepatocellular carcinoma. Hepatology. 56:2277–2287. 2012. View Article : Google Scholar : PubMed/NCBI | |
Kim M, Lee HC, Tsedensodnom O, Hartley R, Lim YS, Yu E, Merle P and Wands JR: Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol. 48:780–791. 2008. View Article : Google Scholar : PubMed/NCBI | |
Wong CM, Fan ST and Ng IO: Beta-Catenin mutation and overexpression in hepatocellular carcinoma: Clinicopathologic and prognostic significance. Cancer. 92:136–145. 2001. View Article : Google Scholar : PubMed/NCBI | |
Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya F, et al: Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet. 44:760–764. 2012. View Article : Google Scholar : PubMed/NCBI | |
Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, et al: Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 44:694–698. 2012. View Article : Google Scholar : PubMed/NCBI | |
Guan YS, La Z, Yang L, He Q and Li P: p53 gene in treatment of hepatic carcinoma: Status quo. World J Gastroenterol. 13:985–992. 2007. View Article : Google Scholar : PubMed/NCBI | |
Staib F, Hussain SP, Hofseth LJ, Wang XW and Harris CC: TP53 and liver carcinogenesis. Hum Mutat. 21:201–216. 2003. View Article : Google Scholar : PubMed/NCBI | |
Hussain SP, Schwank J, Staib F, Wang XW and Harris CC: TP53 mutations and hepatocellular carcinoma: Insights into the etiology and pathogenesis of liver cancer. Oncogene. 26:2166–2176. 2007. View Article : Google Scholar : PubMed/NCBI | |
Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI | |
Bressac B, Kew M, Wands J and Ozturk M: Selective G to T Mutation Of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 350:429–431. 1991. View Article : Google Scholar : PubMed/NCBI | |
Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ and Harris CC: Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 350:427–428. 1991. View Article : Google Scholar : PubMed/NCBI | |
Oda T, Tsuda H, Scarpa A, Sakamoto M and Hirohashi S: p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res. 52:6358–6364. 1992.PubMed/NCBI | |
Zhou JD, Shen F, Ji JS, Zheng K, Huang M and Wu JC: FAM9C plays an anti-apoptotic role through activation of the PI3K/Akt pathway in human hepatocellular carcinoma. Oncol Rep. 30:1275–1284. 2013.PubMed/NCBI | |
Liu J, Zhang C, Lin M, Zhu W, Liang Y, Hong X, Zhao Y, Young KH, Hu W and Feng Z: Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma. Oncotarget. 5:2635–2647. 2014. View Article : Google Scholar : PubMed/NCBI | |
Pellegrino R, Calvisi DF, Neumann O, Kolluru V, Wesely J, Chen X, Wang C, Wuestefeld T, Ladu S, Elgohary N, et al: EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma. Hepatology. 59:1886–1899. 2014. View Article : Google Scholar : PubMed/NCBI | |
Zhou Q, Wong CH, Lau CP, Hui CW, Lui VW, Chan SL and Yeo W: enhanced antitumor activity with combining effect of mTOR inhibition and microtubule stabilization in hepatocellular carcinoma. Int J Hepatol. 2013:1038302013. View Article : Google Scholar : PubMed/NCBI | |
Khare S, Zhang Q and Ibdah JA: Epigenetics of hepatocellular carcinoma: Role of microRNA. World J Gastroenterol. 19:5439–5445. 2013. View Article : Google Scholar : PubMed/NCBI | |
Law PT and Wong N: Emerging roles of microRNA in the intracellular signaling networks of hepatocellular carcinoma. J Gastroenterol Hepatol. 26:437–449. 2011. View Article : Google Scholar : PubMed/NCBI | |
Zhu Z, Zhang X, Wang G and Zheng H: Role of MicroRNAs in Hepatocellular Carcinoma. Hepat Mon. 14:e186722014. View Article : Google Scholar : PubMed/NCBI | |
Xu L, Beckebaum S, Iacob S, Wu G, Kaiser GM, Radtke A, Liu C, Kabar I, Schmidt HH, Zhang X, et al: MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. J Hepatol. 60:590–598. 2014. View Article : Google Scholar : PubMed/NCBI | |
Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM, Lin CD, Liao YL, Wang JL, Chau YP, et al: MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology. 49:1571–1582. 2009. View Article : Google Scholar : PubMed/NCBI | |
Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP and Zhuang SM: MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology. 50:113–121. 2009. View Article : Google Scholar : PubMed/NCBI | |
Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI | |
Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Croce CM, Bolondi L and Negrini M: MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res. 15:5073–5081. 2009. View Article : Google Scholar : PubMed/NCBI | |
Zhang Y, Takahashi S, Tasaka A, Yoshima T, Ochi H and Chayama K: Involvement of microRNA-224 in cell proliferation, migration, invasion and anti-apoptosis in hepatocellular carcinoma. J Gastroenterol Hepatol. 28:565–575. 2013. View Article : Google Scholar : PubMed/NCBI | |
Tischoff I and Tannapfe A: DNA methylation in hepatocellular carcinoma. World J Gastroenterol. 14:1741–1748. 2008. View Article : Google Scholar : PubMed/NCBI | |
Liew CT, Li HM, Lo KW, Leow CK, Chan JY, Hin LY, Lau WY, Lai PB, Lim BK, Huang J, et al: High frequency of p16INK4A gene alterations in hepatocellular carcinoma. Oncogene. 18:789–795. 1999. View Article : Google Scholar : PubMed/NCBI | |
Qin Y, Liu JY, Li B, Sun ZL and Sun ZF: Association of low p16INK4a and p15INK4b mRNAs expression with their CpG islands methylation with human hepatocellular carcinogenesis. World J Gastroenterol. 10:1276–1280. 2004.PubMed/NCBI | |
Mori T, Nomoto S, Koshikawa K, Fujii T, Sakai M, Nishikawa Y, Inoue S, Takeda S, Kaneko T and Nakao A: Decreased expression and frequent allelic inactivation of the RUNX3 gene at 1p36 in human hepatocellular carcinoma. Liver Int. 25:380–388. 2005. View Article : Google Scholar : PubMed/NCBI | |
Park WS, Cho YG, Kim CJ, Song JH, Lee YS, Kim SY, Nam SW, Lee SH, Yoo NJ and Lee JY: Hypermethylation of the RUNX3 gene in hepatocellular carcinoma. Exp Mol Med. 37:276–281. 2005. View Article : Google Scholar : PubMed/NCBI | |
Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC and Herman JG: SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet. 28:29–35. 2001. View Article : Google Scholar : PubMed/NCBI | |
Okochi O, Hibi K, Sakai M, Inoue S, Takeda S, Kaneko T and Nakao A: Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis. Clin Cancer Res. 9:5295–5298. 2003.PubMed/NCBI | |
Shih YL, Shyu RY, Hsieh CB, Lai HC, Liu KY, Chu TY and Lin YW: Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma. Cancer. 107:579–590. 2006. View Article : Google Scholar : PubMed/NCBI | |
Huang J, Zhang YL, Teng XM, Lin Y, Zheng DL, Yang PY and Han ZG: Down-regulation of SFRP1 as a putative tumor suppressor gene can contribute to human hepatocellular carcinoma. BMC cancer. 7:1262007. View Article : Google Scholar : PubMed/NCBI | |
Zhang YJ, Chen Y, Ahsan H, Lunn RM, Lee PH, Chen CJ and Santella RM: Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relationship to aflatoxin B1-DNA adducts and p53 mutation in hepatocellular carcinoma. Int J Cancer. 103:440–444. 2003. View Article : Google Scholar : PubMed/NCBI | |
Matsukura S, Soejima H, Nakagawachi T, Yakushiji H, Ogawa A, Fukuhara M, Miyazaki K, Nakabeppu Y, Sekiguchi M and Mukai T: CpG methylation of MGMT and hMLH1 promoter in hepatocellular carcinoma associated with hepatitis viral infection. Br J Cancer. 88:521–529. 2003. View Article : Google Scholar : PubMed/NCBI | |
Li Z, Zhang H, Yang J, Hao T and Li S: Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma. Cell Biol Int. 36:427–432. 2012. View Article : Google Scholar : PubMed/NCBI | |
Schagdarsurengin U, Wilkens L, Steinemann D, Flemming P, Kreipe HH, Pfeifer GP, Schlegelberger B and Dammann R: Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene. 22:1866–1871. 2003. View Article : Google Scholar : PubMed/NCBI | |
Hu L, Chen G, Yu H and Qiu X: Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. Hepatol Int. 4:423–432. 2010. View Article : Google Scholar : PubMed/NCBI | |
Xu B, Di J, Wang Z, Han X, Li Z, Luo X and Zheng Q: Quantitative analysis of RASSF1A promoter methylation in hepatocellular carcinoma and its prognostic implications. Biochem Biophys Res Commun. 438:324–328. 2013. View Article : Google Scholar : PubMed/NCBI | |
Zhong S, Tang MW, Yeo W, Liu C, Lo YM and Johnson PJ: Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. Clin Cancer Res. 8:1087–1092. 2002.PubMed/NCBI | |
Midorikawa Y, Makuuchi M, Tang W and Aburatani H: Microarray-based analysis for hepatocellular carcinoma: From gene expression profiling to new challenges. World J Gastroenterol. 13:1487–1492. 2007. View Article : Google Scholar : PubMed/NCBI | |
Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, Tsunoda T, Furukawa Y and Nakamura Y: Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: Identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res. 61:2129–2137. 2001.PubMed/NCBI | |
Shirota Y, Kaneko S, Honda M, Kawai HF and Kobayashi K: Identification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays. Hepatology. 33:832–840. 2001. View Article : Google Scholar : PubMed/NCBI | |
Nomoto S, Kanda M, Okamura Y, Nishikawa Y, Qiyong L, Fujii T, Sugimoto H, Takeda S and Nakao A: Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis. Ann Surg Oncol. 17:923–932. 2010. View Article : Google Scholar : PubMed/NCBI | |
Zhang LH and Ji JF: Molecular profiling of hepatocellular carcinomas by cDNA microarray. World J Gastroenterol. 11:463–468. 2005. View Article : Google Scholar : PubMed/NCBI | |
Kanda M, Nomoto S, Okamura Y, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S and Nakao A: Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Int J Oncol. 35:477–483. 2009.PubMed/NCBI | |
Okamura Y, Nomoto S, Kanda M, Li Q, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S and Nakao A: Leukemia inhibitory factor receptor (LIFR) is detected as a novel suppressor gene of hepatocellular carcinoma using double-combination array. Cancer Lett. 289:170–177. 2010. View Article : Google Scholar : PubMed/NCBI | |
Kanda M, Nomoto S, Okamura Y, Hayashi M, Hishida M, Fujii T, Nishikawa Y, Sugimoto H, Takeda S and Nakao A: Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma. Mol Carcinog. 50:571–579. 2011. View Article : Google Scholar : PubMed/NCBI | |
Okamura Y, Nomoto S, Kanda M, Hayashi M, Nishikawa Y, Fujii T, Sugimoto H, Takeda S and Nakao A: Reduced expression of reelin (RELN) gene is associated with high recurrence rate of hepatocellular carcinoma. Ann Surg Oncol. 18:572–579. 2011. View Article : Google Scholar : PubMed/NCBI | |
Hayashi M, Nomoto S, Kanda M, Okamura Y, Nishikawa Y, Yamada S, Fujii T, Sugimoto H, Takeda S and Kodera Y: Identification of the A kinase anchor protein 12 (AKAP12) gene as a candidate tumor suppressor of hepatocellular carcinoma. J Surg Oncol. 105:381–386. 2012. View Article : Google Scholar : PubMed/NCBI | |
Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF and Wong N: MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology. 135:257–269. 2008. View Article : Google Scholar : PubMed/NCBI | |
Shen J, Wang S, Zhang YJ, Kappil M, Wu HC, Kibriya MG, Wang Q, Jasmine F, Ahsan H, Lee PH, et al: Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology. 55:1799–1808. 2012. View Article : Google Scholar : PubMed/NCBI | |
Okamura Y, Nomoto S, Hayashi M, Hishida M, Nishikawa Y, Yamada S, Fujii T, Sugimoto H, Takeda S, Kodera Y and Nakao A: Identification of the bleomycin hydrolase gene as a methylated tumor suppressor gene in hepatocellular carcinoma using a novel triple-combination array method. Cancer Lett. 312:150–157. 2011. View Article : Google Scholar : PubMed/NCBI | |
Hishida M, Nomoto S, Inokawa Y, Hayashi M, Kanda M, Okamura Y, Nishikawa Y, Tanaka C, Kobayashi D, Yamada S, et al: Estrogen receptor 1 gene as a tumor suppressor gene in hepatocellular carcinoma detected by triple-combination array analysis. Int J Oncol. 43:88–94. 2013.PubMed/NCBI | |
Inokawa Y, Nomoto S, Hishida M, Hayashi M, Kanda M, Nishikawa Y, Takeda S, Sugimoto H, Fujii T, Yamada S and Kodera Y: Detection of doublecortin domain-containing 2 (DCDC2), a new candidate tumor suppressor gene of hepatocellular carcinoma, by triple combination array analysis. J Exp Clin Cancer Res. 32:652013. View Article : Google Scholar : PubMed/NCBI | |
Inokawa Y, Nomoto S, Hishida M, Hayashi M, Kanda M, Nishikawa Y, Takeda S, Fujiwara M, Koike M, Sugimoto H, et al: Dynamin 3: A new candidate tumor suppressor gene in hepatocellular carcinoma detected by triple combination array analysis. Onco Targets Ther. 6:1417–1424. 2013. View Article : Google Scholar : PubMed/NCBI | |
Hayashi M, Nomoto S, Hishida M, Inokawa Y, Kanda M, Okamura Y, Nishikawa Y, Tanaka C, Kobayashi D, Yamada S, et al: Identification of the collagen type 1 α 1 gene (COL1A1) as a candidate survival-related factor associated with hepatocellular carcinoma. BMC Cancer. 14:1082014. View Article : Google Scholar : PubMed/NCBI | |
Takano N, Hishida M, Inokawa Y, Hayashi M, Kanda M, Nishikawa Y, Iwata N, Kobayashi D, Tanaka C, Yamada S, et al: CCNJ detected by triple combination array analysis as a tumor-related gene of hepatocellular carcinoma. Int J Oncol. 46:1963–70. 2015.PubMed/NCBI | |
Hishida M, Inokawa Y, Takano N, Nishikawa Y, Iwata N, Kanda M, Tanaka C, Kobayashi D, Yamada S, Nakayama G, et al: Protein tyrosine kinase 7: A hepatocellular carcinoma-related gene detected by triple-combination array. J Surg Res. 195:444–453. 2015. View Article : Google Scholar : PubMed/NCBI | |
Revill K, Wang T, Lachenmayer A, Kojima K, Harrington A, Li J, Hoshida Y, Llovet JM and Powers S: Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma. Gastroenterology. 145:1424–1435. 2013. View Article : Google Scholar : PubMed/NCBI | |
Nishida N, Nishimura T, Nakai T, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, et al: Genome-wide profiling of DNA methylation and tumor progression in human hepatocellular carcinoma. Dig Dis. 32:658–663. 2014. View Article : Google Scholar : PubMed/NCBI | |
Sherman M: Hepatocellular carcinoma: Epidemiology, surveillance, and diagnosis. Semin Liver Dis. 30:3–16. 2010. View Article : Google Scholar : PubMed/NCBI | |
Fattovich G, Stroffolini T, Zagni I and Donato F: Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology. 127:5:Suppl 1. S35–S50. 2004. View Article : Google Scholar : PubMed/NCBI | |
Ladep NG, Lesi OA, Mark P, Lemoine M, Onyekwere C, Afihene M, Crossey MM and Taylor-Robinson SD: Problem of hepatocellular carcinoma in West Africa. World J Hepatol. 6:783–792. 2014. View Article : Google Scholar : PubMed/NCBI | |
Perz JF, Armstrong GL, Farrington LA, Hutin YJ and Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 45:529–538. 2006. View Article : Google Scholar : PubMed/NCBI | |
Kao JH and Chen DS: Global control of hepatitis B virus infection. Lancet Infect Dis. 2:395–403. 2002. View Article : Google Scholar : PubMed/NCBI | |
Lavanchy D: The global burden of hepatitis C. Liver Int. 29(Suppl 1): S74–S81. 2009. View Article : Google Scholar | |
El-Serag HB: Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 36(5): Suppl 1. S74–S83. 2002. View Article : Google Scholar : PubMed/NCBI | |
Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, Decarli A, Trevisi P, Ribero ML, Martelli C, et al: Alcohol and hepatocellular carcinoma: The effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol. 155:323–331. 2002. View Article : Google Scholar : PubMed/NCBI | |
Baffy G, Brunt EM and Caldwell SH: Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace. J Hepatol. 56:1384–1391. 2012. View Article : Google Scholar : PubMed/NCBI | |
White DL, Kanwal F and El-Serag HB: Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 10:1342–1359. 2012. View Article : Google Scholar : PubMed/NCBI | |
Poon RT, Fan ST, Lo CM, Liu CL and Wong J: Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: Implications for a strategy of salvage transplantation. Ann Surg. 235:373–382. 2002. View Article : Google Scholar : PubMed/NCBI | |
Senthilnathan S, Memon K, Lewandowski RJ, et al: Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: Analyzing patterns of progression in 285 patients. Hepatology. 55:1432–1442. 2012. View Article : Google Scholar : PubMed/NCBI | |
Zhou XD, Tang ZY, Yang BH, Lin ZY, Ma ZC, Ye SL, Wu ZQ, Fan J, Qin LX and Zheng BH: Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer. 91:1479–1486. 2001. View Article : Google Scholar : PubMed/NCBI | |
Shimada M, Hamatsu T, Yamashita Y, Rikimaru T, Taguchi K, Utsunomiya T, Shirabe K and Sugimachi K: Characteristics of multicentric hepatocellular carcinomas: Comparison with intrahepatic metastasis. World J Surg. 25:991–995. 2001. View Article : Google Scholar : PubMed/NCBI | |
Wang B, Xia CY, Lau WY, Lu XY, Dong H, Yu WL, Jin GZ, Cong WM and Wu MC: Determination of clonal origin of recurrent hepatocellular carcinoma for personalized therapy and outcomes evaluation: A new strategy for hepatic surgery. J Am Coll Surg. 217:1054–1062. 2013. View Article : Google Scholar : PubMed/NCBI | |
Nomoto S, Yamashita K, Koshikawa K, Nakao A and Sidransky D: Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma. Clin Cancer Res. 8:481–487. 2002.PubMed/NCBI | |
Nomoto S, Kinoshita T, Kato K, Otani S, Kasuya H, Takeda S, Kanazumi N, Sugimoto H and Nakao A: Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Br J Cancer. 97:1260–1265. 2007. View Article : Google Scholar : PubMed/NCBI | |
Nomoto S, Hishida M, Inokawa Y, Sugimoto H and Kodera Y: Management of hepatocellular carcinoma should consider both tumor factors and background liver factors. Hepatobiliary Surg Nutr. 3:82–85. 2014.PubMed/NCBI | |
Utsunomiya T, Shimada M, Morine Y, Tajima A and Imoto I: Specific molecular signatures of non-tumor liver tissue may predict a risk of hepatocarcinogenesis. Cancer Sci. 105:749–754. 2014. View Article : Google Scholar : PubMed/NCBI | |
Utsunomiya T, Shimada M, Imura S, Morine Y, Ikemoto T and Mori M: Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. J Gastroenterol. 45:146–152. 2010. View Article : Google Scholar : PubMed/NCBI | |
Okamoto M, Utsunomiya T, Wakiyama S, Hashimoto M, Fukuzawa K, Ezaki T, Hanai T, Inoue H and Mori M: Specific gene-expression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients. Ann Surg Oncol. 13:947–954. 2006. View Article : Google Scholar : PubMed/NCBI | |
Utsunomiya T, Ishikawa D, Asanoma M, Yamada S, Iwahashi S, Kanamoto M, Arakawa Y, Ikemoto T, Morine Y, Imura S, et al: Specific miRNA expression profiles of non-tumor liver tissue predict a risk for recurrence of hepatocellular carcinoma. Hepatol Res. 44:631–638. 2014. View Article : Google Scholar : PubMed/NCBI | |
Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, et al: Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 359:1995–2004. 2008. View Article : Google Scholar : PubMed/NCBI | |
Nomoto S, Hishida M, Inokawa Y, Takano N, Kanda M, Nishikawa Y, Fujii T, Koike M, Sugimoto H and Kodera Y: Expression analysis of THOP1 in background liver, a prognostic predictive factor in hepatocellular carcinoma, extracted by multiarray analysis. Ann Surg Oncol. 21(Suppl 3): S443–S450. 2014. View Article : Google Scholar : PubMed/NCBI | |
Sonohara F, Nomoto S, Inokawa Y, Hishida M, Takano N, Kanda M, Nishikawa Y, Fujii T, Koike M, Sugimoto H and Kodera Y: High expression of Janus kinase 2 in background normal liver tissue of resected hepatocellular carcinoma is associated with worse prognosis. Oncol Rep. 33:767–773. 2015.PubMed/NCBI | |
Ammerpohl O, Pratschke J, Schafmayer C, Haake A, Faber W, von Kampen O, Brosch M, Sipos B, von Schönfels W, Balschun K, et al: Distinct DNA methylation patterns in cirrhotic liver and hepatocellular carcinoma. Int J Cancer. 130:1319–1328. 2012. View Article : Google Scholar : PubMed/NCBI | |
Um TH, Kim H, Oh BK, Kim MS, Kim KS, Jung G and Park YN: Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J Hepatol. 54:939–947. 2011. View Article : Google Scholar : PubMed/NCBI | |
Arai E, Ushijima S, Gotoh M, Ojima H, Kosuge T, Hosoda F, Shibata T, Kondo T, Yokoi S, Imoto I, et al: Genome-wide DNA methylation profiles in liver tissue at the precancerous stage and in hepatocellular carcinoma. Int J Cancer. 125:2854–2862. 2009. View Article : Google Scholar : PubMed/NCBI | |
Yoshida T, Kato J, Maekita T, Yamashita S, Enomoto S, Ando T, Niwa T, Deguchi H, Ueda K, Inoue I, et al: Altered mucosal DNA methylation in parallel with highly active Helicobacter pylori-related gastritis. Gastric Cancer. 16:488–497. 2013. View Article : Google Scholar : PubMed/NCBI | |
Lee KH, Hwang D, Kang KY, Lee S, Kim DY, Joo YE and Lee JH: Frequent promoter methylation of CDH1 in non-neoplastic mucosa of sporadic diffuse gastric cancer. Anticancer Res. 33:3765–3774. 2013.PubMed/NCBI | |
Kadara H, Fujimoto J, Yoo SY, Maki Y, Gower AC, Kabbout M, Garcia MM, Chow CW, Chu Z, Mendoza G, et al: Transcriptomic architecture of the adjacent airway field cancerization in non-small cell lung cancer. J Natl Cancer Inst. 106:dju0042014. View Article : Google Scholar : PubMed/NCBI | |
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI | |
Zheng Z, Liang W, Wang D, Schroder PM, Ju W, Wu L, Zheng Z, Shang Y, Guo Z and He X: Adjuvant chemotherapy for patients with primary hepatocellular carcinoma: A meta-analysis. Int J Cancer. 136:E751–E759. 2015. View Article : Google Scholar : PubMed/NCBI | |
Kubo S, Takemura S, Sakata C, Urata Y and Uenishi T: Adjuvant therapy after curative resection for hepatocellular carcinoma associated with hepatitis virus. Liver Cancer. 2:40–46. 2013. View Article : Google Scholar : PubMed/NCBI |